CTIS2023-503719-13-00招募中1 期
A randomized, double-blind, multi-center, placebo-controlled, parallel-group phase 3 study to compare the efficacy, acceptability, and safety of Tranexamic Acid Oral Solution 5% with placebo in the prevention of clinically relevant bleeding events in subjects treated with direct oral anticoagulants or vitamin K antagonists and undergoing a single or multiple tooth extraction - HYL-P004-003
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 356
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Provide their signed study informed consent to participate., Subject with hemoglobin = 12.0 g/dL (male) or = 11.0 g/dL (female)., Willing to avoid alcohol consumption for the duration of the study, Willing and able to adhere to the study assessment schedule and other protocol requirements as evidenced by a written informed consent, Negative pregnancy test in females of childbearing potential at Screening and Day 1 visit., Women must be post-menopausal (defined as no menses for 12 months without an alternative medical cause), surgically sterile, or willing to use highly effective method of birth control which is defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly (refer to Table 4 for further information on acceptable and unacceptable birth control methods). The Investigator is responsible for determining whether the subject has adequate birth control for study participation, Male or female = 18 years of age at screening., Body mass index (BMI) between 18.5 kg/m2 and 35 kg/m2, inclusively and body weight = 50 kg., Treated regularly for = 3 months with direct oral anticoagulant (e.g., edoxaban, apixaban, rivaroxaban, dabigatran) or vitamin K antagonists (e.g., acenocoumarol, warfarin, etc.)., Subjects on VKAs can be enrolled if the subject’s International Normalized Ratio (INR) at screening, but not more than 5 days before the dental extraction procedure is within the range of 2.0-3.5., Subjects taking VKAs or DOACs can be enrolled if these are prescribed and used according to the approved product label, Scheduled to undergo a single or multiple tooth extraction, Considered as reasonably healthy to follow the study procedures as documented by the medical history, physical examination, and vital sign assessments, Subjects with a platelet count of 100,000-500,000 (inclusive) platelets per microliter
排除标准
- •Any coagulation disorders requiring TXA., Use of hormonal methods of birth control that increase the risk of thrombosis (e.g., estrogen-containing contraceptives). Refer to Table 4 in protocol Section 8.2.11 for further information on acceptable and unacceptable birth control methods., Requires tooth extraction for orthodontic reason, History of severe allergy or allergic reactions or hypersensitivity to the study drug or any component of its formulations or related drugs or heparin, Subjects with type II, III and IV periodontitis (as per American Dental Association Classification) (see Appendix 1)., History of subarachnoid hemorrhage., Active intravascular clotting (defined as a history of thrombosis within the past 3 months)., Blood in the urine (macroscopic hematuria) at Screening., Renal function test result of estimated glomerular filtration rate = 15 mL/min/1.73 m² at Screening., Any ongoing or planned dual anti-platelet treatment for the duration of subject`s participation in the study (any 2 of the following: aspirin, dipyridamole, or any thienopyridine, i.e., clopidogrel, prasugrel, ticlopidine, ticagrelor). However, subjects receiving a very low dose aspirin (= 160 mg) may be enrolled., Women with intended pregnancy or breast-feeding, Any ongoing or planned oncological treatment for the duration of subject`s participation in the study, Any immunocompromising condition., Use of any recreational drugs or history of drug addiction., Positive alcohol breath test at Screening and Day 1., Participating in any other clinical study or has received treatment with any investigational drug or device within 3 months prior to screening., History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of the investigational drug, might affect interpretation of the results of the study, or renders the subject at high risk for treatment complications (including but not limited to diseases such as uncontrolled diabetes, any haemato-oncological condition [e.g., leukemia], any congenital hematological condition [e.g., hemophilia])., Severe uncontrolled arterial hypertension, e.g., > 200 mmHg systolic or > 110 mmHg diastolic blood pressure at two consecutive readings, Subjects who are found positive to human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) serological tests.
研究者
相似试验
进行中（未招募）
1 期
A randomized, double-blind, multi-center, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal woman taking calcium and vitamin DThe trial is Phase III.The population will be healthy post-menopausal women who are between 60 and 85 years of ageEUCTR2005-002984-10-GBordic Bioscience4,500
进行中（未招募）
不适用
A randomized, double-blind, multi-center, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal woman taking calcium and vitamin DEUCTR2005-002984-10-DKordic Bioscience4,662
进行中（未招募）
1 期
A randomized, double-blind, multi-center, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal woman taking calcium and vitamin DThe trial is Phase III.The population will be healthy post-menopausal women who are between 55 and 85 years of ageMedDRA version: 9.1Level: LLTClassification code 10031282Term: OsteoporosisEUCTR2005-002984-10-CZordic Bioscience4,662
进行中（未招募）
不适用
Clinical study to evaluate the efficacy and safety of diclofenac potassium 25 mg tablets in subjects with acute joint paiankle sprain, grade I - IIMedDRA version: 14.1Level: LLTClassification code 10002549Term: Ankle sprainSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2011-005577-23-DEovartis Consumer Health
进行中（未招募）
不适用
A randomized, double-blind, multi-center, placebo-controlled, parallel group study to evaluate the efficacy and safety of diclofenac sodium topical gel 1% applied four times daily in subjects with acute ankle spraiAnkle sprain, Grade I-IIMedDRA version: 12.1Level: LLTClassification code 10002549Term: Ankle sprainEUCTR2010-020935-38-DEovartis Consumer Health